208 related articles for article (PubMed ID: 17895404)
1. FCRL1 on chronic lymphocytic leukemia, hairy cell leukemia, and B-cell non-Hodgkin lymphoma as a target of immunotoxins.
Du X; Nagata S; Ise T; Stetler-Stevenson M; Pastan I
Blood; 2008 Jan; 111(1):338-43. PubMed ID: 17895404
[TBL] [Abstract][Full Text] [Related]
2. Technology evaluation: BL22, NCI.
Barth S
Curr Opin Mol Ther; 2002 Feb; 4(1):72-5. PubMed ID: 11883697
[TBL] [Abstract][Full Text] [Related]
3. Hairy cell leukemia, a B-cell neoplasm that is particularly sensitive to the cytotoxic effect of anti-Tac(Fv)-PE38 (LMB-2).
Robbins DH; Margulies I; Stetler-Stevenson M; Kreitman RJ
Clin Cancer Res; 2000 Feb; 6(2):693-700. PubMed ID: 10690555
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias.
Kreitman RJ; Margulies I; Stetler-Stevenson M; Wang QC; FitzGerald DJ; Pastan I
Clin Cancer Res; 2000 Apr; 6(4):1476-87. PubMed ID: 10778980
[TBL] [Abstract][Full Text] [Related]
5. Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display.
Salvatore G; Beers R; Margulies I; Kreitman RJ; Pastan I
Clin Cancer Res; 2002 Apr; 8(4):995-1002. PubMed ID: 11948105
[TBL] [Abstract][Full Text] [Related]
6. The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin 1 in B-cell lymphomas through CD22 upregulation and PKC-βII depletion.
Biberacher V; Decker T; Oelsner M; Wagner M; Bogner C; Schmidt B; Kreitman RJ; Peschel C; Pastan I; Meyer Zum Büschenfelde C; Ringshausen I
Haematologica; 2012 May; 97(5):771-9. PubMed ID: 22180432
[TBL] [Abstract][Full Text] [Related]
7. Fc receptor-like 1-5 molecules are similarly expressed in progressive and indolent clinical subtypes of B-cell chronic lymphocytic leukemia.
Kazemi T; Asgarian-Omran H; Hojjat-Farsangi M; Shabani M; Memarian A; Sharifian RA; Razavi SM; Jeddi-Tehrani M; Rabbani H; Shokri F
Int J Cancer; 2008 Nov; 123(9):2113-9. PubMed ID: 18704934
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of Fc receptor-like 1 in patients with chronic lymphocytic leukemia, hairy cell leukemia, and various B-cell non-Hodgkin's lymphoma.
Yousefi Z; Eskandari N
Leuk Res Rep; 2019; 12():100181. PubMed ID: 31467839
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies.
Kreitman RJ; Squires DR; Stetler-Stevenson M; Noel P; FitzGerald DJ; Wilson WH; Pastan I
J Clin Oncol; 2005 Sep; 23(27):6719-29. PubMed ID: 16061911
[TBL] [Abstract][Full Text] [Related]
10. CD21(-/low) marginal zone B cells highly express Fc receptor-like 5 protein and are killed by anti-Fc receptor-like 5 immunotoxins in hepatitis C virus-associated mixed cryoglobulinemia vasculitis.
Terrier B; Nagata S; Ise T; Rosenzwajg M; Pastan I; Klatzmann D; Saadoun D; Cacoub P
Arthritis Rheumatol; 2014 Feb; 66(2):433-43. PubMed ID: 24504816
[TBL] [Abstract][Full Text] [Related]
11. Immunoglobulin superfamily receptor translocation associated 2 protein on lymphoma cell lines and hairy cell leukemia cells detected by novel monoclonal antibodies.
Ise T; Maeda H; Santora K; Xiang L; Kreitman RJ; Pastan I; Nagata S
Clin Cancer Res; 2005 Jan; 11(1):87-96. PubMed ID: 15671532
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies.
Kreitman RJ; Wilson WH; White JD; Stetler-Stevenson M; Jaffe ES; Giardina S; Waldmann TA; Pastan I
J Clin Oncol; 2000 Apr; 18(8):1622-36. PubMed ID: 10764422
[TBL] [Abstract][Full Text] [Related]
13. Targeting malignant B cells with an immunotoxin against ROR1.
Baskar S; Wiestner A; Wilson WH; Pastan I; Rader C
MAbs; 2012; 4(3):349-61. PubMed ID: 22531447
[TBL] [Abstract][Full Text] [Related]
14. Cortactin expression in non-Hodgkin B-cell lymphomas: a new marker for the differential diagnosis between chronic lymphocytic leukemia and mantle cell lymphoma.
Pizzi M; Trentin L; Visentin A; Saraggi D; Martini V; Guzzardo V; Righi S; Frezzato F; Piazza F; Sabattini E; Semenzato G; Rugge M
Hum Pathol; 2019 Mar; 85():251-259. PubMed ID: 30458196
[TBL] [Abstract][Full Text] [Related]
15. Three new monoclonal antibodies that define a unique antigen associated with prolymphocytic leukemia/non-Hodgkin's lymphoma and are effectively internalized after binding to the cell surface antigen.
Okazaki M; Luo Y; Han T; Yoshida M; Seon BK
Blood; 1993 Jan; 81(1):84-94. PubMed ID: 8417805
[TBL] [Abstract][Full Text] [Related]
16. Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial.
Wayne AS; Kreitman RJ; Findley HW; Lew G; Delbrook C; Steinberg SM; Stetler-Stevenson M; Fitzgerald DJ; Pastan I
Clin Cancer Res; 2010 Mar; 16(6):1894-903. PubMed ID: 20215554
[TBL] [Abstract][Full Text] [Related]
17. Immunopathology of non-Hodgkin lymphomas.
Huber H; Gattringer C; Knapp W; Stein H
Klin Wochenschr; 1984 Nov; 62(21):1001-10. PubMed ID: 6392723
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibodies in the treatment of chronic lymphoid leukemias.
Robak T
Leuk Lymphoma; 2004 Feb; 45(2):205-19. PubMed ID: 15101704
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal antibody studies in B(non-T)-cell malignancies.
Shimoyama M; Minato K; Tobinai K; Nagai M; Hirose M
Jpn J Clin Oncol; 1983 Sep; 13(3):477-88. PubMed ID: 6417373
[TBL] [Abstract][Full Text] [Related]
20. Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity.
Du X; Beers R; Fitzgerald DJ; Pastan I
Cancer Res; 2008 Aug; 68(15):6300-5. PubMed ID: 18676854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]